Eastern Biotech is pleased to announce its partnership with deCODE genetics to market deCODE’s tests for genetic variants conferring risk of a number of common diseases. The partnership allows Eastern Biotech to offer its clients access to new genetic tests for assessing individual risk of type 2 diabetes mellitus, myocardial infarction, atrial fibrillation, prostate cancer, glaucoma, breast cancer and others that deCODE is developing. All deCODE tests have been validated through clinical trials involving thousands of patients and controls from multiple populations, and have received full regulatory approval. Eastern Biotech aims to become a leading provider of deCODE tests in the UAE and other Middle Eastern Countries.
In the past, Eastern Biotech has introduced to the Middle East products such as CancerSafe, genomic profile tests, family ancestry and other DNA tests. This new range of deCODE genetics tests from type 2 diabetes to common cancers add a whole new dimension to its current range of Predictive Genetic tests.
"Eastern Biotech is committed to provide advanced healthcare solutions to the region" said Dr. Sanjida Ahmed, Director of Research at Eastern Biotech. "We are constantly on the search for new breakthroughs and we are proud of our collaboration with deCODE. We are very excited to be offering this new and growing product range, which is going to be very useful for the UAE and Middle East populations.” She added.
Pankaj Sohaney, Manager Marketing said "The demand for genetic testing services in the region is increasing. We receive regular enquiries from all GCC countries. This partnership ensures that we are able to provide our customers with the widest range of high quality genetic tests."
Genetic testing is becoming an increasingly important component of modern healthcare as the focus shifts from intervention to prevention. An awareness of clinical predisposition to the development of disease provides us critical lead time for the implementation of vital pre-emptive and precautionary measures such as dietary factors, detailed screening or pharmaceutical intervention. Eastern Biotech’s agreement with deCODE ensures that local clinicians can provide their patients with the most accurate and timely information to delay or prevent the onset of diseases such as diabetes, heart disease and certain cancers.
About Eastern Biotech & Life Sciences
Eastern Biotech & Life Sciences (easternbiotech.com) is established within DuBiotech, the biotechnology park in Dubai since November 2005. Its vision is to promote the health of the people of the United Arab Emirates and the region through the introduction of biotechnological products and systems, and through research into the diseases relevant to this region, especially Genetic Disorders, Obesity, Diabetes and Heart disease.
Eastern Biotech is working as a clinical reference laboratory for various genetic and cytogenetic testing services in Middle East region through their test centers. Eastern Biotech is a pioneer in this region for online predictive genetic services, and has seen tremendous growth in the last 2 years.
deCODE is a biopharmaceutical company applying its discoveries in human genetics and its capabilities in chemistry and structural biology to the development of drugs and diagnostics for common diseases. deCODE’s therapeutics programs include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer’s disease and other conditions. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProCa™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma; and deCODE BreastCancer™ for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM for our pioneering personal genome analysis service, integrating the genetic variants included in these tests and those linked to another twenty common diseases.